Revista clinica espanola最新文献

{"title":"Usage of lipid-lowering therapies in patients at high and very high cardiovascular risk from Spain: One-year follow-up of the Spanish subpopulation from the European SANTORINI study.","authors":"José María Mostaza, Carlos Lahoz, Manuel García de Yébenes Castro, José Manuel Rubio Campal, Eddy Velásquez, Amaia Ibarra Gutiérrez, Jose Francisco Díaz, Nuria Plana, Moisés Rodríguez-Mañero, Juan de Dios García-Díaz, Francisco Martínez Debén, Isabel Pavón de Paz, Alberico L Catapano, Gema Díaz Moya, Kausik K Ray","doi":"10.1016/j.rceng.2025.502344","DOIUrl":"https://doi.org/10.1016/j.rceng.2025.502344","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world studies evaluating the impact of 2019 European Societies of Cardiology (ESC) and Atherosclerosis (EAS) guidelines on the use of lipid-lowering treatments (LLTs) are scarce. This manuscript shows baseline and 1-year follow-up data on LLT usage and low-density lipoprotein cholesterol (LDL-C) goal attainment in the Spanish subpopulation from SANTORINI study and put them in perspective with the European cohort without Spanish participants.</p><p><strong>Methods: </strong>SANTORINI was a multinational, prospective, non-interventional study. The Spanish subpopulation involved up to 1018 patients at high and very high cardiovascular (CV) risk.</p><p><strong>Results: </strong>Of 956 patients in LDL-C dataset, mean LDL-C levels decreased from baseline (82.7 ± 40.6 mg/dL) to 1-year follow-up (72.3 ± 32.6 mg/dL), in patients at high and very high risk. The percentage of patients who achieved 2019 ESC/EAS LDL-C goals increased from 26.5% at baseline to 34.1% at 1-year follow-up, in patients at high (23.1% versus 27.3%) and very high risk (27.9% versus 37.0%). Attainment to LDL-C targets improved while initiating treatment with a LLT in patients not receiving it at baseline or following change to a combination therapy in those who were receiving it. During the follow-up, seven patients died due to CV causes, and 46 and 24 had at least one four- or three-component major adverse CV events, respectively.</p><p><strong>Conclusions: </strong>Follow-up data from SANTORINI Spain show that LLT usage increased from baseline, including monotherapy and combination therapy. Despite recommendations, patients at highest CV risk continue not receiving the most adequate LLT for reducing LDL-C levels in routine clinical practice.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":"502344"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update of the SEIOMM clinical guideline of osteoporosis: Abaloparatide.","authors":"J A Riancho, M Martín Millán, P Peris, G Martínez","doi":"10.1016/j.rceng.2025.502338","DOIUrl":"https://doi.org/10.1016/j.rceng.2025.502338","url":null,"abstract":"<p><strong>Introduction: </strong>Osteoporosis is a highly prevalent condition. SEIOMM has published guidelines for managing these patients in 2022. The recent introduction of a new drug in Europe, abaloparatide, makes it advisable to consider its role among therapeutic options.</p><p><strong>Objective and results: </strong>This article summarizes the existing information on the efficacy and safety of abaloparatide and it updates the therapeutic algorithms proposed in the guidelines.</p><p><strong>Conclusion: </strong>Abaloparatide is an osteoanabolic drug with efficacy and safety similar to teriparatide. It represents a new option for treating patients with severe osteoporosis and a very high risk of fracture.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":"502338"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination in chronic obstructive pulmonary disease (COPD): Scientific evidence and strategies to reduce risks.","authors":"Ó Porto Fuentes, A Muela Molinero, M B Alonso Ortiz","doi":"10.1016/j.rceng.2025.502330","DOIUrl":"10.1016/j.rceng.2025.502330","url":null,"abstract":"<p><p>Patients with chronic obstructive pulmonary disease (COPD) are more vulnerable to infections that may favor disease progression. Vaccination in COPD is an effective intervention that helps reduce infectious exacerbations, as well as associated morbidity and mortality. In recent years, the use of new vaccines has become widespread, not only targeting specific infections but also contributing to long-lasting immunity and slowing the process of immune aging (immunosenescence). Current clinical practice guidelines recommend the administration of six vaccines (against Streptococcus pneumoniae, influenza virus, SARS-CoV-2, respiratory syncytial virus, Bordetella pertussis, and varicella-zoster virus) for all COPD patients. However, vaccination rates in many countries still fall short of the established targets. Therefore, it is crucial to design a specific vaccination schedule tailored for COPD patients.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":"502330"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert consensus on interstitial lung disease associated with systemic autoimmune diseases. Executive summary.","authors":"A González-García, M Akasbi, M P Brito-Zerón, J L Callejas, I Cusacovich, F Jiménez Segovia, M Martín Cascón, S Prieto-González, L Sáez Comet, C P Simeón, R Solans Laque, J S García Morillo","doi":"10.1016/j.rceng.2025.502326","DOIUrl":"10.1016/j.rceng.2025.502326","url":null,"abstract":"<p><p>Interstitial lung disease (ILD) is a frequent and potentially fatal manifestation of systemic autoimmune diseases (SAD). Early screening, diagnosis, and treatment with immunomodulators, and in some cases, antifibrotics, as well as appropriate follow-up, are essential to improving patients' quality of life and survival. The complexity of these diseases and the limited robust evidence to guide clinical decision-making lead to significant variability in management guidelines. In this article, a group of experts in SAD has developed recommendations for the screening, diagnosis, treatment, and follow-up of ILD, considering the latest evidence, their clinical experience, and the results of a survey conducted among specialists. The diseases included are systemic sclerosis, Sjögren's disease, idiopathic inflammatory myopathy, ANCA-associated vasculitis, sarcoidosis and systemic lupus erythematosus.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":"502326"},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conscientious objection to medical aid in dying: Knowledge, attitudes, and practices in primary care.","authors":"R Triviño-Caballero, J Franco, L Sordo","doi":"10.1016/j.rceng.2025.502329","DOIUrl":"10.1016/j.rceng.2025.502329","url":null,"abstract":"<p><strong>Background/objective: </strong>The Euthanasia Regulation Law includes the right to conscientious objection (CO). However, there is hardly any information available on its exercise or the grounds for objection. The objective of this study was to identify knowledge, attitudes, and practices (KAP) regarding CO to the provision of medical aid in dying (MAID) in primary care, which is the level of care where most provisions occur.</p><p><strong>Materials and methods: </strong>Cross-sectional KAP model study. A total of 434 active General Practitioners (GPs) working in health centres across Spain were surveyed through self-administered questionnaires on knowledge, attitudes, and practices related to CO. A descriptive analysis of the responses in each domain was performed, followed by multivariate analyses to determine the factors related to having objected or considering doing so.</p><p><strong>Results: </strong>Of the GPs surveyed, 46.3% practised in Madrid. 75.2% were women, with an average age of 47. 84.8% had received training in bioethics. 54.9% reported knowing the law, only 29% correctly answered questions about CO in end-of-life practices. 35% had objected or considered objecting. Higher rates of objection were observed among those practising in Madrid (aOR = 2.98; 95% CI 1.16-5.34), those with religious beliefs (aOR = 5.23; 95% CI 2.78-9.80), and those opposed to MAID (aOR = 12.63; 95% CI 5.80-27.50).</p><p><strong>Conclusions: </strong>The main reasons for objecting are moral and emotional, although other contextual factors also emerge. Given the high level of ignorance of the practices to which one can object, improvements in training and institutional involvement are needed for responsible practice and to guarantee the MAID.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":"502329"},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peer-assisted learning enhances non-technical skills in pediatric physical therapy education.","authors":"T T Ma, Q Zhang, H B Zhao, H X Li","doi":"10.1016/j.rceng.2025.502328","DOIUrl":"10.1016/j.rceng.2025.502328","url":null,"abstract":"","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":"502328"},"PeriodicalIF":0.0,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144478390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment to the special article \"Utility of point-of-care ultrasound (POCUS) in hospitalized patients with acute confusional syndrome of unclear etiology\".","authors":"J A Mariz","doi":"10.1016/j.rceng.2025.502334","DOIUrl":"10.1016/j.rceng.2025.502334","url":null,"abstract":"","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":"502334"},"PeriodicalIF":0.0,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144478388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Counter-reply: Comment to the special article \"Utility of point-of-care ultrasound (POCUS) in hospitalized patients with acute confusional syndrome of unclear etiology\".","authors":"S Carrasco-Molina, Á Robles-Marhuenda, J J Ríos-Blanco, Y Tung-Chen","doi":"10.1016/j.rceng.2025.502337","DOIUrl":"10.1016/j.rceng.2025.502337","url":null,"abstract":"","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":"502337"},"PeriodicalIF":0.0,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144478389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The future impact of advanced imaging and artificial intelligence on the diagnosis and R&D of rare diseases.","authors":"M Moreno-Higueras, G Fatoul-Del Pino, S García-Linares, T Martín-Noguerol","doi":"10.1016/j.rceng.2025.502327","DOIUrl":"10.1016/j.rceng.2025.502327","url":null,"abstract":"","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":"502327"},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of the appearance of radiological alterations at 12 months after COVID-19 pneumonia.","authors":"C Roig-Martí, I Pérez-Catalán, S Folgado-Escudero, M Varea-Villanueva, Antonio Navarro-Ballester, M P Fernández-García, A Segura-Fábrega, M-L Mateu-Campos, J Usó-Blasco, J-M Ramos-Rincón","doi":"10.1016/j.rceng.2025.502325","DOIUrl":"10.1016/j.rceng.2025.502325","url":null,"abstract":"<p><strong>Background and objective: </strong>The radiological evolution after COVID-19 pneumonia is unknown. We propose to analyze the main radiological findings one year after COVID-19 pneumonia, as well as identify possible factors that may influence it.</p><p><strong>Material and methods: </strong>Cohort study of patients with COVID-19 pneumonia undergoing high-resolution computed tomography (HRCT) 12 months after hospital discharge. A descriptive study of the radiological findings and a multivariate analysis are carried out to identify the factors of the appearance of radiological anomalies.</p><p><strong>Results: </strong>n = 139 patients, with a mean age of 63 years and 66.2% male. The most frequent radiological findings were ground-glass opacities (59%), followed by bronchiectasis (42.4%), subpleural parenchymal bands (32.4%), atelectasis (13.7%), septal thickening (12.9%) and fibrotic tracts (9.4%). Male sex was associated with the presence of bronchiectasis (ORa = 3.55; p = 0.026), peak admission IL-6 levels > 133 ng/L with the detection of subpleural parenchymal bands (ORa = 3.58; p = 0.048) and obesity with the occurrence of atelectasis (ORa = 3.70; p = 0.014). Systemic corticotherapy during admission decreased the risk of fibrotic tracts (ORa = 0.02; p = 0.003).</p><p><strong>Conclusions: </strong>Lung damage persists with high frequency one year after COVID-19 pneumonia. Male sex, high peak admission IL-6 levels and obesity were risk factors for radiological abnormalities while systemic corticosteroid therapy decreased the occurrence of fibrotic tracts 12 months after hospital admission.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":"502325"},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}